The US Food and Drug Administration approved Eli Lilly and Company's JAK inhibitor Olumiant (baricitinib) for the treatment of severe alopecia areata, marking the first systemic treatment approved for the disorder that can cause patchy baldness. With the 13 June approval, Lilly beat a close rival, Pfizer Inc., to the market.
The FDA approved Olumiant for rheumatoid arthritis in 2018, but the drug has faced a challenging commercial market due to...







